news
Press release
 
March 15, 2017
Corindus Announces Partnership with WakeMed Health & Hospitals
WALTHAM, MA — MARCH 15, 2017 — Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS] today announced that WakeMed Health & Hospitals will partner with Corindus to develop a national center of excellence to advance patient care and clinical robotics research and to train interventional cardiologists on robotic-assisted percutaneous coronary interventions ("PCI") using the CorPath GRX System. WakeMed Health & Hospitals is the leading provider of health and cardiovascular services in Wake County, North Carolina.

"I am proud to be part of a health system that represents the best training, the latest technologies and the highest commitment to patient care, safety and innovation," said Frances O. Wood, M.D., FACC, interventional cardiologist and co-director of Structural Heart at WakeMed Heart Center. "CorPath GRX will transform the way we perform PCI, improving care and quality of life for our patients. I look forward to partnering with Corindus to build best-in-class medical education to train physicians and staff, to advance the body of clinical research on robotics, and to help shape the robotic system of the future."

WakeMed Health & Hospitals purchased three CorPath GRX Systems to develop a vascular robotics program. The CorPath GRX System is designed to treat patients undergoing PCI and builds on the CorPath platform with the addition of important key features that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. In addition, the System protects physicians and staff from the occupational hazards of working with radiation exposure in the cath lab.

Mark J. Toland, President and CEO of Corindus, stated, "Our top priority is to provide the best care possible for patients through precision medicine while protecting the physicians performing these life-saving procedures. Our partnership with leading clinical facilities such as the WakeMed Heart Center can accelerate the research, education and adoption of this important technology in cath labs across the United States."
About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200
kate.stanton@corindus.com

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
ir@corindus.com
 
close the window

Please complete the form below in order to download the content.








right
close the window

Please complete the form below in order to download the content.







close the window

Please fill out this brief form to subscribe to our email newsletter.





close the window

Please complete the form below and a member of our Clinical team will contact you.






close the window

Please complete the form below in order to download the content.







close the window
Thank you for subscribing to our newsletter. You will now receive email updates from Corindus.